1. Imatinib plasma levels in the management of cutaneous side effects induced by imatinib (Glivec®): 2 cases reports
- Author
-
Mohamed Lakhal, Emna Gaïes, Riadh Daghfous, Sameh Trabelsi, Sihem El Aïdli, S. Srairi, Anis Klouz, and Rim Sahnoun
- Subjects
Male ,Gynecology ,medicine.medical_specialty ,business.industry ,Pruritus ,Antineoplastic Agents ,General Medicine ,Exanthema ,Middle Aged ,Piperazines ,Pyrimidines ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Benzamides ,Imatinib Mesylate ,Humans ,Medicine ,Female ,Drug Eruptions ,business ,Aged - Abstract
Imatinib, an antineoplastic drug used to treat certain cancers, has many side effects such as hematologic, neurologic or cutaneous toxicity. These toxicities seem to be due to a high imatinib plasmatic concentration and are frequently controlled by a discontinuation or a dosage reduction of the drug. We report here in 2 cases of cutaneous side effects induced by imatinib in order to demonstrate the necessity of drug monitoring in such cases. In our cases, imatinib is responsible in the occurrence of these side effects. Monitoring plasma levels of imatinib allowed us to judge if levels were toxic or not and to avoid discontinuation of imatinib in some cases.
- Published
- 2013